Table 1.

Immune receptors encoded by genes in the leukocyte receptor complex region on human chromosome 19q13.4.
 Common names and CD designations of the receptors are indicated. Functions and associations with adapter proteins are implied based on structural characteristics of the receptors, but have only been validated experimentally for a few of the receptors, usually when a ligand has been identified. As indicated, certain KIR2DL recognize a dimorphic polymorphism in HLA-C at positions 77 and 80 in the α1 helix of the class I heavy chain. N77K80 and S77N80 refer to the amino acids (single letter code) present at residues 77 and 80 in HLA-C, conferring specificity for the indicated KIR. * = KIR2DL2 and KIR2DL3 are alleles of the same locus; KIR3DL1 and KIR3DS1 are alleles of the same locus. All other receptors listed are encoded by separate genes, although many of these genes also demonstrate allelic polymorphism.

NamesCDFunctionSignalingLigand
ILT5 / LIR3 / LILRB3 CD85a Inhibition ITIM  
ILT8 / LILRB6 CD85b Activation FcεRIγ  
LIR8 / LILRB5 CD85c Inhibition ITIM  
ILT4 / LIR2 / LILRB2 CD85d Inhibition ITIM HLA class I 
ILT6 / LIR4 / LILRA3 CD85e Soluble  
ILT11 / LILRB7 CD85f Activation FcεRIγ  
ILT7 / LILRA4 CD85g Activation FcεRIγ  
LAIR-1  Inhibition ITIM  
LAIR-2  Soluble receptor   
ILT1 / LIR7 / LILRA2 CD85h Activation FcεRIγ  
LIR6 / LILRA1 CD85i Activation FcεRIγ  
ILT2 / LIR1/ LILRB1 CD85j Inhibition ITIM HLA class I, CMV UL18 
ILT3 / LIR5/ LILRB4 CD85k Inhibition ITIM  
ILT9 / LILRA6 CD85l Pseudogene   
ILT10 / LILRA5 CD85m Activation FcεRIγ  
KIR3DL3 CD158z Inhibition ITIM  
KIR2DL3* CD158b2 Inhibition ITIM HLA-C S77/N80 
KIR2DL2* CD158b1 Inhibition ITIM HLA-C S77/N80 
KIR2DL1 CD158a Inhibition ITIM HLA-C N77/K80 
KIR2DL4 CD158d Inhibition/ Activation? ITIM / ?  
KIR3DL1* CD158e1 Inhibition ITIM HLA-Bw4 
KIR3DS1* CD158e2 Activation DAP12  
KIR2DL5A CD158f Inhibition ITIM  
KIR2DL5B  Inhibition ITIM  
KIR2DS3  Activation DAP12  
KIR2DS5 CD158g Activation DAP12  
KIR2DS1 CD158h Activation DAP12 HLA-C, weakly 
KIR2DS2 CD158j Activation DAP12  
KIR2DS4 CD158i Activation DAP12 HLA-C, weakly 
KIR3DL2 CD158k Inhibition ITIM HLA-A? 
FcαR CD89 Activation FcεRIγ IgA 
NKp46  Activation FcεRIγ, ζ  
NamesCDFunctionSignalingLigand
ILT5 / LIR3 / LILRB3 CD85a Inhibition ITIM  
ILT8 / LILRB6 CD85b Activation FcεRIγ  
LIR8 / LILRB5 CD85c Inhibition ITIM  
ILT4 / LIR2 / LILRB2 CD85d Inhibition ITIM HLA class I 
ILT6 / LIR4 / LILRA3 CD85e Soluble  
ILT11 / LILRB7 CD85f Activation FcεRIγ  
ILT7 / LILRA4 CD85g Activation FcεRIγ  
LAIR-1  Inhibition ITIM  
LAIR-2  Soluble receptor   
ILT1 / LIR7 / LILRA2 CD85h Activation FcεRIγ  
LIR6 / LILRA1 CD85i Activation FcεRIγ  
ILT2 / LIR1/ LILRB1 CD85j Inhibition ITIM HLA class I, CMV UL18 
ILT3 / LIR5/ LILRB4 CD85k Inhibition ITIM  
ILT9 / LILRA6 CD85l Pseudogene   
ILT10 / LILRA5 CD85m Activation FcεRIγ  
KIR3DL3 CD158z Inhibition ITIM  
KIR2DL3* CD158b2 Inhibition ITIM HLA-C S77/N80 
KIR2DL2* CD158b1 Inhibition ITIM HLA-C S77/N80 
KIR2DL1 CD158a Inhibition ITIM HLA-C N77/K80 
KIR2DL4 CD158d Inhibition/ Activation? ITIM / ?  
KIR3DL1* CD158e1 Inhibition ITIM HLA-Bw4 
KIR3DS1* CD158e2 Activation DAP12  
KIR2DL5A CD158f Inhibition ITIM  
KIR2DL5B  Inhibition ITIM  
KIR2DS3  Activation DAP12  
KIR2DS5 CD158g Activation DAP12  
KIR2DS1 CD158h Activation DAP12 HLA-C, weakly 
KIR2DS2 CD158j Activation DAP12  
KIR2DS4 CD158i Activation DAP12 HLA-C, weakly 
KIR3DL2 CD158k Inhibition ITIM HLA-A? 
FcαR CD89 Activation FcεRIγ IgA 
NKp46  Activation FcεRIγ, ζ  

or Create an Account

Close Modal
Close Modal